tiprankstipranks
Trending News
More News >
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
US Market
Advertisement

IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

Compare
565 Followers
See the Price Targets and Ratings of:

IDYA Analyst Ratings

Strong Buy
9Ratings
Strong Buy
7 Buy
2 Hold
0 Sell
Based on 9 analysts giving stock ratings to
IDEAYA
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IDYA Stock 12 Month Forecast

Average Price Target

$42.00
▲(71.08% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $42.00 with a high forecast of $72.00 and a low forecast of $25.00. The average price target represents a 71.08% change from the last price of $24.55.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","28":"$28","43":"$43","58":"$58","73":"$73"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$72.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,28,43,58,73],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.27,27.94153846153846,31.613076923076925,35.284615384615385,38.956153846153846,42.62769230769231,46.299230769230775,49.970769230769235,53.642307692307696,57.31384615384616,60.98538461538462,64.65692307692308,68.32846153846154,{"y":72,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.27,25.633846153846154,26.997692307692308,28.361538461538462,29.725384615384616,31.08923076923077,32.45307692307692,33.816923076923075,35.18076923076923,36.54461538461538,37.90846153846154,39.27230769230769,40.636153846153846,{"y":42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.27,24.326153846153847,24.38230769230769,24.43846153846154,24.494615384615383,24.55076923076923,24.606923076923078,24.663076923076922,24.71923076923077,24.775384615384617,24.83153846153846,24.88769230769231,24.943846153846152,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.46,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.73,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$72.00Average Price Target$42.00Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on IDYA
Leerink Partners
Leerink Partners
$27
Hold
9.98%
Upside
Reiterated
08/06/25
IDEAYA Biosciences: Hold Rating Amid Key Pipeline Developments and Anticipated Clinical Milestones
RBC Capital Analyst forecast on IDYA
RBC Capital
RBC Capital
$30
Buy
22.20%
Upside
Reiterated
08/05/25
RBC Capital Remains a Buy on IDEAYA Biosciences (IDYA)
LifeSci Capital Analyst forecast on IDYA
LifeSci Capital
LifeSci Capital
$58
Buy
136.25%
Upside
Reiterated
08/05/25
IDEAYA Biosciences: Promising Clinical Data and Strong Financial Health Support Buy Rating
TD Cowen
Buy
Reiterated
08/05/25
IDEAYA Biosciences: Promising Catalysts and Late-Stage Developments Fuel Buy RatingWe estimate peak daro sales of $1.6B by 2035, which includes $655MM of US neoadjuvant and $410MM of 1L mUM sales.
Oppenheimer Analyst forecast on IDYA
Oppenheimer
Oppenheimer
$37
Buy
50.71%
Upside
Reiterated
08/05/25
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC) and IDEAYA Biosciences (NASDAQ: IDYA)
TR | OpenAI - 4o Analyst forecast on IDYA
TR | OpenAI - 4o
TR | OpenAI - 4o
$23.5$26
Hold
5.91%
Upside
Reiterated
07/31/25
AI Generated ArticleAI Generated Article
Mizuho Securities Analyst forecast on IDYA
Mizuho Securities
Mizuho Securities
$55$43
Buy
75.15%
Upside
Reiterated
07/29/25
Mizuho Securities Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
J.P. Morgan Analyst forecast on IDYA
J.P. Morgan
J.P. Morgan
$66$72
Buy
193.28%
Upside
Reiterated
07/28/25
JPMorgan ups Ideaya target, adds to Analyst Focus ListJPMorgan ups Ideaya target, adds to Analyst Focus List
Goldman Sachs Analyst forecast on IDYA
Goldman Sachs
Goldman Sachs
$25
Hold
1.83%
Upside
Initiated
07/10/25
IDEAYA Biosciences (IDYA) Receives a Hold from Goldman Sachs
Wells Fargo
$44
Buy
79.23%
Upside
Initiated
06/26/25
Ideaya Biosciences initiated with an Overweight at Wells FargoIdeaya Biosciences initiated with an Overweight at Wells Fargo
Wedbush Analyst forecast on IDYA
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$52
Buy
111.81%
Upside
Initiated
05/07/25
Wedbush Analyst forecast on IDYA
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$52
Buy
111.81%
Upside
Initiated
04/15/25
BTIG
$62
Buy
152.55%
Upside
Reiterated
04/14/25
IDEAYA Biosciences: Promising Prospects with Strategic Phase 3 Trial and Key Data Catalysts
Stephens
$51
Buy
107.74%
Upside
Initiated
11/18/24
Ideaya Biosciences initiated with an Overweight at StephensIdeaya Biosciences initiated with an Overweight at Stephens
Stifel Nicolaus Analyst forecast on IDYA
Stifel Nicolaus
Stifel Nicolaus
$66$64
Buy
160.69%
Upside
Reiterated
11/06/24
IDEAYA Biosciences (IDYA) Gets a Buy from Stifel Nicolaus
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on IDYA
Leerink Partners
Leerink Partners
$27
Hold
9.98%
Upside
Reiterated
08/06/25
IDEAYA Biosciences: Hold Rating Amid Key Pipeline Developments and Anticipated Clinical Milestones
RBC Capital Analyst forecast on IDYA
RBC Capital
RBC Capital
$30
Buy
22.20%
Upside
Reiterated
08/05/25
RBC Capital Remains a Buy on IDEAYA Biosciences (IDYA)
LifeSci Capital Analyst forecast on IDYA
LifeSci Capital
LifeSci Capital
$58
Buy
136.25%
Upside
Reiterated
08/05/25
IDEAYA Biosciences: Promising Clinical Data and Strong Financial Health Support Buy Rating
TD Cowen
Buy
Reiterated
08/05/25
IDEAYA Biosciences: Promising Catalysts and Late-Stage Developments Fuel Buy RatingWe estimate peak daro sales of $1.6B by 2035, which includes $655MM of US neoadjuvant and $410MM of 1L mUM sales.
Oppenheimer Analyst forecast on IDYA
Oppenheimer
Oppenheimer
$37
Buy
50.71%
Upside
Reiterated
08/05/25
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC) and IDEAYA Biosciences (NASDAQ: IDYA)
TR | OpenAI - 4o Analyst forecast on IDYA
TR | OpenAI - 4o
TR | OpenAI - 4o
$23.5$26
Hold
5.91%
Upside
Reiterated
07/31/25
AI Generated ArticleAI Generated Article
Mizuho Securities Analyst forecast on IDYA
Mizuho Securities
Mizuho Securities
$55$43
Buy
75.15%
Upside
Reiterated
07/29/25
Mizuho Securities Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
J.P. Morgan Analyst forecast on IDYA
J.P. Morgan
J.P. Morgan
$66$72
Buy
193.28%
Upside
Reiterated
07/28/25
JPMorgan ups Ideaya target, adds to Analyst Focus ListJPMorgan ups Ideaya target, adds to Analyst Focus List
Goldman Sachs Analyst forecast on IDYA
Goldman Sachs
Goldman Sachs
$25
Hold
1.83%
Upside
Initiated
07/10/25
IDEAYA Biosciences (IDYA) Receives a Hold from Goldman Sachs
Wells Fargo
$44
Buy
79.23%
Upside
Initiated
06/26/25
Ideaya Biosciences initiated with an Overweight at Wells FargoIdeaya Biosciences initiated with an Overweight at Wells Fargo
Wedbush Analyst forecast on IDYA
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$52
Buy
111.81%
Upside
Initiated
05/07/25
Wedbush Analyst forecast on IDYA
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$52
Buy
111.81%
Upside
Initiated
04/15/25
BTIG
$62
Buy
152.55%
Upside
Reiterated
04/14/25
IDEAYA Biosciences: Promising Prospects with Strategic Phase 3 Trial and Key Data Catalysts
Stephens
$51
Buy
107.74%
Upside
Initiated
11/18/24
Ideaya Biosciences initiated with an Overweight at StephensIdeaya Biosciences initiated with an Overweight at Stephens
Stifel Nicolaus Analyst forecast on IDYA
Stifel Nicolaus
Stifel Nicolaus
$66$64
Buy
160.69%
Upside
Reiterated
11/06/24
IDEAYA Biosciences (IDYA) Gets a Buy from Stifel Nicolaus
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering IDEAYA Biosciences

1 Month
xxx
Success Rate
9/15 ratings generated profit
60%
Average Return
+3.73%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +3.73% per trade.
3 Months
xxx
Success Rate
12/19 ratings generated profit
63%
Average Return
+8.09%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.16% of your transactions generating a profit, with an average return of +8.09% per trade.
1 Year
Charles ZhuLifeSci Capital
Success Rate
13/19 ratings generated profit
68%
Average Return
+32.78%
reiterated a buy rating 27 days ago
Copying Charles Zhu's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +32.78% per trade.
2 Years
xxx
Success Rate
12/19 ratings generated profit
63%
Average Return
+31.46%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.16% of your transactions generating a profit, with an average return of +31.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDYA Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
13
14
15
10
6
Buy
0
0
0
2
4
Hold
8
7
7
11
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
21
22
23
20
In the current month, IDYA has received 10 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. IDYA average Analyst price target in the past 3 months is 42.00.
Each month's total comprises the sum of three months' worth of ratings.

IDYA Financial Forecast

IDYA Earnings Forecast

Next quarter’s earnings estimate for IDYA is -$0.84 with a range of -$1.01 to -$0.63. The previous quarter’s EPS was -$0.88. IDYA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.55% of the time in the same period. In the last calendar year IDYA has Outperformed its overall industry.
Next quarter’s earnings estimate for IDYA is -$0.84 with a range of -$1.01 to -$0.63. The previous quarter’s EPS was -$0.88. IDYA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.55% of the time in the same period. In the last calendar year IDYA has Outperformed its overall industry.

IDYA Sales Forecast

Next quarter’s sales forecast for IDYA is $4.36M with a range of $0.00 to $12.50M. The previous quarter’s sales results were $0.00. IDYA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 43.89% of the time in the same period. In the last calendar year IDYA has Outperformed its overall industry.
Next quarter’s sales forecast for IDYA is $4.36M with a range of $0.00 to $12.50M. The previous quarter’s sales results were $0.00. IDYA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 43.89% of the time in the same period. In the last calendar year IDYA has Outperformed its overall industry.

IDYA Stock Forecast FAQ

What is IDYA’s average 12-month price target, according to analysts?
Based on analyst ratings, IDEAYA Biosciences’s 12-month average price target is 42.00.
    What is IDYA’s upside potential, based on the analysts’ average price target?
    IDEAYA Biosciences has 71.08% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IDYA a Buy, Sell or Hold?
          IDEAYA Biosciences has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.
            What is IDEAYA Biosciences’s price target?
            The average price target for IDEAYA Biosciences is 42.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $72.00 ,the lowest forecast is $25.00. The average price target represents 71.08% Increase from the current price of $24.55.
              What do analysts say about IDEAYA Biosciences?
              IDEAYA Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of IDYA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis